STOCK TITAN

IM Cannabis to Report Fourth Quarter & Full Year 2022 Financial Results on Wednesday, March 29 at 9:00am ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

IM Cannabis Corp. (IMC) will release its financial results for the fourth quarter and full year ended December 31, 2022, on March 29, 2023, before market open. The Company will host a Zoom web conference call at 9:00 a.m. ET to discuss these results. IMC is focusing its operations in high-value markets, specifically Israel and Germany, as it exits operations in Canada to enhance sustainable growth. IMC aims to leverage its data-driven ecosystem to improve compliance and product delivery in these markets.

Positive
  • Focus on high-value markets, Israel and Germany, for sustainable growth.
  • Exit from Canada operations allows for better resource allocation.
Negative
  • Discontinuation of Canadian operations may result in loss of revenue.
  • Shift in focus could lead to transitional challenges in business strategy.

TORONTO and GLIL YAM, Israel, March 15, 2023 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022 on Wednesday, March 29, 2023, before the market opens.

IM Cannabis Corp. Logo

The Company will host a zoom web conference call on the same day at 9:00 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.

If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently commenced exiting operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp. and its wholly-owned subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company's Canadian operation continues to export premium and ultra-premium medical cannabis to Israel. The Company is exiting operations in Canada and considers these operations discontinued. For more information, please visit www.imcannabis.com.

Company Contact:
Maya Lustig, Director Investor & Public Relations
IM Cannabis Corp. +972-54-677-8100
maya.l@imcannabis.com

Oren Shuster, CEO
IM Cannabis Corp.
O: +972-77-3603504
E: info@imcannabis.com 

Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

 

Cision View original content:https://www.prnewswire.com/news-releases/im-cannabis-to-report-fourth-quarter--full-year-2022-financial-results-on-wednesday-march-29-at-900am-et-301772758.html

SOURCE IM Cannabis Corp.

FAQ

When will IM Cannabis report its Q4 and full year 2022 financial results?

IM Cannabis will report its financial results on March 29, 2023.

What time is the IM Cannabis conference call scheduled for?

The conference call is scheduled for 9:00 a.m. ET on March 29, 2023.

What markets is IM Cannabis focusing on after exiting Canada?

IM Cannabis is focusing on Israel and Germany for its operations.

How can investors access the recording of the IM Cannabis conference call?

The recording will be available on the IM Cannabis investor website within 24 hours after the call.

IM Cannabis Corp. Common Shares

NASDAQ:IMCC

IMCC Rankings

IMCC Latest News

IMCC Stock Data

6.20M
878.59k
47%
6.13%
0.13%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tel Aviv